<DOC>
	<DOCNO>NCT02592967</DOCNO>
	<brief_summary>The purpose study determine recommend Phase 2 dose ( RP2D ) JNJ-64041757 live attenuate double delete ( LADD ) Listeria monocytogenes ( bacteria two virulence gene , encode molecule help cause disease , remove ) administer intravenously participant advance ( Stage IIIb ) metastatic ( Stage IV ) NSCLC ( adenocarcinoma ) .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity JNJ-64041757 , Live-attenuated Double-deleted Listeria Immunotherapy , Subjects With Non Small Cell Lung Cancer</brief_title>
	<detailed_description>This first-in-human ( FIH ) , Phase 1 , open-label , multicenter 2-part study participant advance ( Stage IIIb ) metastatic ( Stage IV ) non-small cell lung cancer ( NSCLC ) ( adenocarcinoma ) . Part 1 study Dose Escalation phase determine recommend Phase 2 dose ( RP2D ) base safety pharmacodynamic assessment Part 2 Dose Expansion Phase evaluate 2 expansion cohort ( Cohort 2A 2B ) RP2D JNJ-64041757 determine Part 1 . The study consist Screening Period ( sign inform consent immediately first dose ) , open-label Treatment Period ( first dose study drug End-of-Treatment Visit ) ; Post treatment Follow-up Period ( End-of Treatment Visit study discontinuation ) . Dose limit toxicity ( DLT ) part 1 , antigen-specific T-cell response part 2 incidence adverse event part primarily evaluate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Diseaserelated criterion Part 1 Part 2 : 1 ) Histologically cytologically document nonsmall cell lung cancer ( NSCLC ) adenocarcinoma ; 2 ) Stage III b IV disease ; 3 ) Tested presence echinoderm microtubuleassociated proteinlike 4 anaplastic lymphoma kinase ( EML4ALK ) rearrangement ; 4 ) Received least 2 prior line Food Drug Administration ( FDA ) approve systemic therapy , one therapy platinumcontaining regimen OR fail complete firstline platinumcontaining regimen refuse secondline regimen despite informed different therapeutic option specific clinical benefit investigator ; content inform consent discussion include therapeutic option review investigator need document subject need sign specific consent form ; Diseaserelated criterion Cohort 2B : 1 ) Mesothelin protein overexpression , define immunohistochemistry ( IHC ) detection protein great equal ( &gt; = ) 50 percent ( % ) tumor cell archive tumor material ; 2 ) Primary tumor metastatic lesion ( ) amenable tumor core biopsy At least 1 measurable tumor lesion per RECIST v1.1 ( exception : subject Part 1 required present measurable disease ) Eastern Cooperative Oncology Group ( ECOG ) Performance status score 0 1 At least 28 day since last chemotherapy immunotherapy prior first dose ; least 14 day since last radiation prior first dose ( exception : palliative radiotherapy pain use great equal ( &gt; = ) 7 day prior infusion ) Untreated brain metastasis . Subjects must complete treatment brain metastasis , neurologically stable steroid , least 28 day prior first dose study drug History listeriosis vaccination listeriabased vaccine prophylactic vaccine ( eg , influenza , pneumococcal , diphtheria , tetanus , pertussis [ dTP/dTAP ] ) within 28 day study treatment Known allergy penicillin trimethoprim/sulfamethoxazole . Participants allergic one antibiotic allow enroll Concurrent treatment antiTumor necrosis factor alpha ( TNF alpha ) therapy , systemic corticosteroid ( prednisone dose great [ &gt; ] 10 mg per day equivalent ) immune suppressive drug within 2 week prior Screening . Steroids topical , inhaled , nasal ( spray ) ophthalmic solution permit Positive test result human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome ( AIDS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>JNJ-64041757</keyword>
	<keyword>Listeria monocytogenes</keyword>
</DOC>